Trident IWR allows set-up, monitoring, and maintenance of study requirements and supplies.
GlaxoSmithKline (GSK) entered into a multiyear agreement with BioClinica to deploy the latter’s Trident IWR (interactive web response) system across its Phase I–IV trials. Trident IWR’s design provides clinical operation personnel with the ability to set up, monitor, and maintain randomization and supplies for their clinical trials.
Trident IWR delivers study setup without the need for programming while simultaneously providing IVR system phone support through the same simplified configuration process. It was designed by the team that reportedly created the world’s first parameter-driven IWR for a top five global pharmaceutical company.
That software, designed by Tourtellotte Solutions, a company that BioClinica acquired in September 2009, is currently being used in more than 150 active clinical trials, and has been used in more than 300 trials since its inception, according to BioClinica.
“GSK had a requirement for a new solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident,” notes Mark Weinstein, CEO of BioClinica. “We look forward to supporting GSK so that they can successfully deploy and utilize our software in their upcoming studies.”
